Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent-Reference-Cited by-同舟云学术

Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent

Published:2018-06-21 Issue:7 Volume:29 Page:2448-2454
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Bandara Nilantha¹,Jacobson Orit²,Mpoy Cedric¹,Chen Xiaoyuan²,Rogers Buck E.¹^ORCID

Affiliation:

1. Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri 63108, United States

2. Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, United States

Funder

Department of Radiation Oncology, Washington University in St. Louis

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.8b00341

Reference42 articles.

1. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy

2. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

3. Opportunities in somatostatin research: biological, chemical and therapeutic aspects

4. Gastroenteropancreatic neuroendocrine tumours

5. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-15

2. Effect of Linker Entities on Pharmacokinetics of ¹¹¹In-Labeled Prostate-Specific Membrane Antigen-Targeting Ligands with an Albumin Binder;ACS Pharmacology & Translational Science;2024-07-09

3. Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study;Acta Pharmaceutica Sinica B;2024-05

4. Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands;Pharmaceuticals;2024-02-16

5. Theranostics in Neuroendocrine Tumors;Molecular Imaging and Targeted Therapy;2023